WANG Yani, WU Di, RAO Zhi, LI Maoxing, XI Rui, REN Jun. Interaction between cyclosporine A and voriconazole in patients with allogeneic hematopoietic stem cell transplantation[J]. Journal of Pharmaceutical Practice and Service, 2022, 40(3): 277-280. doi: 10.12206/j.issn.1006-0111.202111056
Citation:
|
WANG Yani, WU Di, RAO Zhi, LI Maoxing, XI Rui, REN Jun. Interaction between cyclosporine A and voriconazole in patients with allogeneic hematopoietic stem cell transplantation[J]. Journal of Pharmaceutical Practice and Service, 2022, 40(3): 277-280. doi: 10.12206/j.issn.1006-0111.202111056
|
Interaction between cyclosporine A and voriconazole in patients with allogeneic hematopoietic stem cell transplantation
-
WANG Yani1, 2, 3
,
,
-
WU Di1, 3
,
-
RAO Zhi4
,
-
LI Maoxing1, 3
,
-
XI Rui1
,
-
REN Jun1
,
,
- 1.
Department of Clinical Pharmacy, No. 940 Hospital of Joint Logistics Support Force of the PLA, Lanzhou 730050, China
- 2.
Department of Clinical Pharmacy, Traditional Chinese Medicine Hospital of Baoji, Baoji 721000, China
- 3.
School of Pharmacy, Ningxia Medical College, Yinchuan 750001, China
- 4.
Department of Pharmacy, First Hospital of Lanzhou University, Lanzhou 730000, China
- Received Date: 2021-11-12
- Rev Recd Date:
2022-03-16
Available Online:
2023-11-06
- Publish Date:
2022-05-25
-
Abstract
Objective To analyze the drug-drug interaction (DDI) between intravenous voriconazole (VRZ) and intravenous cyclosporine (CsA) in patients after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and provide an individualized and accurate clinical drug delivery. Methods In a self-contrast study, Allo-HSCT patients from January 2019 to December 2019 were enrolled according to the inclusion and exclusion criteria. These patients were treated with CsA and VRZ successively and the blood concentration of CsA and VRZ before and after 5-7 days of VRZ administration were determined with LC-MS/MS. The correlation between the concentration of VRZ and concentration/dose (C/D) ratio of CsA was analyzed with SPSS20.0. Results A total of 15 patients with ALLo-HSCT were enrolled. Wilcoxon sign rank sum test was used to compare the change of median C/D of CsA before and after VRZ administration, which had shown significant difference (P<0.001). Spearman correlation analysis was conducted on the increase of C/D ratio between VRZ and CsA, which had no significant correlation between them (ρ=−0.273, P=0.32). Conclusions There was obvious drug-drug interaction (DDI) between CsA and VRZ. VRZ increased CsA blood concentration significantly, but there was no significant correlation between VRZ blood concentration and the degree of concentration increase, which might be related to individual difference.
-
References
[1]
|
王海涛, 张抗怀, 刘娜, 等. 临床药师对ICU潜在药物相互作用的鉴别和药学干预[J]. 中国医院药学杂志, 2018, 38(16):1747-1749. |
[2]
|
方欢, 曾宏辉, 方忠宏, 等. 临床常见和重要的药物与药物间相互作用[J]. 中国医院用药评价与分析, 2013, 13(3):283-286. |
[3]
|
MORIYAMA B, OBENG A O, BARBARINO J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelin-es for CYP2C19 and voriconazole therapy[J]. Clin Pharmacol Ther,2017,102(1):45-51. doi: 10.1002/cpt.583 |
[4]
|
王亚妮. 异基因造血干细胞移植患者环孢素A和伏立康唑的治疗药物监测[J]. 宁夏:宁夏医科大学, 2020. doi: 10.27258/d.cnki.gnxyc.2020.000051 |
[5]
|
ULLMANN A J, AGUADO J M, ARIKAN-AKDAGLI S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline[J]. Clin Microbiol Infect, 2018, 24(Suppl 1): e1-e38. |
[6]
|
CHEN K, ZHANG X L, KE X Y, et al. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society[J]. Ther Drug Monit,2018,40(6):663-674. doi: 10.1097/FTD.0000000000000561 |
[7]
|
DOLTON M J, MCLACHLAN A J. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity[J]. Int J Antimicrob Agents,2014,44(3):183-193. doi: 10.1016/j.ijantimicag.2014.05.019 |
[8]
|
MELLINGHOFF S C, PANSE J, ALAKEL N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)[J]. Ann Hematol,2018,97(2):197-207. doi: 10.1007/s00277-017-3196-2 |
[9]
|
孙鲁宁, 吴春勇, 赵舜波, 等. 药物对人肝CYP450酶诱导和抑制作用体外评价体系的建立与验证[J]. 药学学报, 2017, 52(12):1924-1932. |
[10]
|
吴劲东, 仇锦春, 张永. 环孢素联用伏立康唑致再生障碍性贫血患儿血压持续升高的药学监护[J]. 医药导报, 2017, 36(12):1419-1421. |
[11]
|
ROMERO A J, POGAMP P L, NILSSON L G, et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients[J]. Clin Pharmacol Ther,2002,71(4):226-234. doi: 10.1067/mcp.2002.121911 |
[12]
|
MASOUMI H T, HADJIBABAIE M, VAEZI M, et al. Evaluation of the interaction of intravenous and oral voriconazole with oral cyclosporine in Iranian HSCT patients[J]. J Res Pharm Pract,2017,6(2):77-82. doi: 10.4103/jrpp.JRPP_16_163 |
-
-
Proportional views
-